Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Allen

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Oncology|June 28, 2022
Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal AdenocarcinomaXin Wang, Osvaldo Espin-Garcia, Di Maria Jiang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss AboutLucy X Ma, Elan D Panov, Michael J Allen, et al.
Nature Communications|May 14, 2024
Long-read powered viral metagenomics in the oligotrophic Sargasso SeaJoanna Warwick-Dugdale, Funing Tian, Michelle L Michelsen, et al.
Science (New York, N.Y.)|August 16, 2005
Complete genome sequence and lytic phase transcription profile of a CoccolithovirusWilliam H Wilson, Declan C Schroeder, Michael J Allen, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
The Oncologist|November 15, 2022
Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal CancerLucy X Ma, Osvaldo Espin-Garcia, Yvonne Bach, et al.
The Oncologist|July 24, 2024
Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapyXin Wang, Michael J Allen, Osvaldo Espin-Garcia, et al.
Journal of Medicinal Chemistry|July 11, 2006
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, Dave E Davies, Anne M Exall, et al.
Journal of Clinical Pathology|September 29, 2021
Molecular characterisation of pancreatic ductal adenocarcinoma with <i>NTRK</i> fusions and review of the literatureMichael J Allen, Amy Zhang, Prashant Bavi, et al.
Journal of Medicinal Chemistry|January 14, 2012
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, John Liddle, Dave E Davies, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Oncology|June 28, 2022
Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal AdenocarcinomaXin Wang, Osvaldo Espin-Garcia, Di Maria Jiang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss AboutLucy X Ma, Elan D Panov, Michael J Allen, et al.
Nature Communications|May 14, 2024
Long-read powered viral metagenomics in the oligotrophic Sargasso SeaJoanna Warwick-Dugdale, Funing Tian, Michelle L Michelsen, et al.
Science (New York, N.Y.)|August 16, 2005
Complete genome sequence and lytic phase transcription profile of a CoccolithovirusWilliam H Wilson, Declan C Schroeder, Michael J Allen, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
The Oncologist|November 15, 2022
Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal CancerLucy X Ma, Osvaldo Espin-Garcia, Yvonne Bach, et al.
The Oncologist|July 24, 2024
Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapyXin Wang, Michael J Allen, Osvaldo Espin-Garcia, et al.
Journal of Medicinal Chemistry|July 11, 2006
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, Dave E Davies, Anne M Exall, et al.
Journal of Clinical Pathology|September 29, 2021
Molecular characterisation of pancreatic ductal adenocarcinoma with <i>NTRK</i> fusions and review of the literatureMichael J Allen, Amy Zhang, Prashant Bavi, et al.
Journal of Medicinal Chemistry|January 14, 2012
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potencyAlan D Borthwick, John Liddle, Dave E Davies, et al.
Pageof 12